Here is our regular summary of content of relevance to neurology from the October 2025 issue of the European Medicines Agency’s (EMA) newsletter.
Key EMA News Updates:
- Upcoming public webinar ‘Shortages: putting patients first’ on Tuesday 4 November at 14:00-16:00 CET.
The webinar will be an opportunity to learn more about the role of the EMA and the EU regulatory network in managing shortages and about the actions that patients, consumers and healthcare professionals can take to prepare for, and help manage, medicine shortages. Click here for more details: Public webinar on shortages: putting patients first | European Medicines Agency (EMA) - A path to better include patients’ perspectives in the regulation of medicines
The EMA released a draft reflection paper on patient experience data, open for consultation until 31 January 2026, outlining principles for integrating patients’ views throughout the medicine lifecycle. Click here for more details: A path to better include patients’ perspectives in the regulation of medicines | European Medicines Agency (EMA) - EMA partners with content creators to promote safe and responsible use of GLP-1 medicines
The EMA launched its first social media campaign, #HealthNotHype, collaborating with content creators to promote safe and informed use of GLP-1 receptor agonists. Click here for more details: EMA partners with content creators to promote safe and responsible use of GLP-1 medicines | European Medicines Agency (EMA) - EMA Management Board: highlights of October 2025 meeting
The EMA Management Board discussed the agency’s mid-year report and endorsed the first EU network data strategy during its October 2025 meeting. Click here for more details: EMA Management Board: highlights of October 2025 meeting | European Medicines Agency (EMA) - EMA confirms suspension of sickle cell disease medicine Oxbryta
The EMA’s CHMP recommended maintaining the suspension of Oxbryta’s marketing authorisation following safety concerns first raised in September 2024. Click here for more details: EMA confirms suspension of sickle cell disease medicine Oxbryta | European Medicines Agency (EMA)
Medicines:
- Leqembi (lecanemab) – indicated for the treatment of Alzheimer’s disease in patients with mild cognitive impairment or mild dementia stage. An additional MRI scan is now recommended before the third infusion of Leqembi (lecanemab), alongside the existing scans before treatment and prior to the 5th, 7th, and 14th infusions. The update aims to enable earlier detection of asymptomatic ARIA and reduce the risk of serious or fatal ARIA-related oedema. Click here for more details: Leqembi – direct healthcare professional communication (DHPC) | European Medicines Agency (EMA)
